The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF
Open accessAbstract
Targeted oncolytic viruses and immunostimulatory therapeutics are being developed as novel cancer treatment platforms. These approaches can be combined through the expression of immunostimulatory cytokines from targeted viruses, including adenoviruses and herpesviruses. Although intratumoral injection of such viruses has been associated with tumor growth inhibition, eradication of distant metastases was not reported. The major limitations for this approach to date have been (1) inefficient intravenous virus delivery to tumors and (2) the lack of predictive, immunocompetent preclinical models. To overcome these hurdles, we developed JX-594, a targeted, thymidine kinase(-) vaccinia virus expressing human GM-CSF (hGM-CSF), for intravenous (i.v.) delivery. We evaluated two immunocompetent liver tumor models: a rabbit model with reproducible, time-dependent metastases to the lungs and a carcinogen-induced rat liver cancer model. Intravenous JX-594 was well tolerated and had highly significant efficacy, including complete responses, against intrahepatic primary tumors in both models. In addition, whereas lung metastases developed in all control rabbits, none of the i.v. JX-594-treated rabbits developed detectable metastases. Tumor-specific virus replication and gene expression, systemically detectable levels of hGM-CSF, and tumor-infiltrating CTLs were also demonstrated. JX-594 holds promise as an i.v.-delivered, targeted virotherapeutic. These two tumor models hold promise for the optimization of this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
Self-citationStojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., & Kirn, D. (2000) · Nature Medicine · doi:10.1038/80474 · Cited by 583
Self-citationRecent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536
Kirn, D., Martuza, R. L., & Zwiebel, J. (2001) · Nature Medicine · doi:10.1038/89901 · Cited by 502
Self-citationYu, Y. A., Shabahang, S., Timiryasova, T. M., Zhang, Q., Beltz, R., Gentschev, I., Goebel, W., & Szalay, A. A. (2004) · Nature Biotechnology · doi:10.1038/nbt937 · Cited by 423
McCart, J. A., Ward, J. M., Lee, J., Hu, Y., Alexander, H. R., Libutti, S. K., Moss, B., & Bartlett, D. L. (2001) · PubMed · Cited by 366
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
Mastrangelo, M. J., Maguire, H. C., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., & Lattime, E. C. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700066 · Cited by 353
Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301377 · Cited by 349
Self-citationPolymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
Fisher, K., Stallwood, Y., Green, N., Ulbrich, K., Mautner, V, & Seymour, L. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301389 · Cited by 316
Alcamí, A., & Smith, G. L. (1995) · Journal of Virology · doi:10.1128/jvi.69.8.4633-4639.1995 · Cited by 301
Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., et al. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301424 · Cited by 283
Self-citationAlcamı́, A., Symons, J. A., & Smith, G. L. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.11230-11239.2000 · Cited by 273
Vanderplasschen, A., Mathew, E., Hollinshead, M., Sim, R. B., & Smith, G. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7544 · Cited by 249
Ramesh, N., Ge, Y., Ennist, D. L., Zhu, M., Mina, M., Ganesh, S., Reddy, P. S., & Yu, D.-C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1059 · Cited by 242
Systemic therapy of myeloma xenografts by an attenuated measles virus
Peng, K.-W., Ahmann, G. J., Pham, L., Greipp, P. R., Cattaneo, R., & Russell, S. J. (2001) · Blood · doi:10.1182/blood.v98.7.2002 · Cited by 181
Chase, M., Chung, R. Y., & Chiocca, E. A. (1998) · Nature Biotechnology · doi:10.1038/nbt0598-444 · Cited by 178
GM-CSF-secreting melanoma vaccines
Dranoff, G. (2003) · Oncogene · doi:10.1038/sj.onc.1206459 · Cited by 166
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides
Peng, K.-W., Facteau, S., Wegman, T., O'Kane, D., & Russell, S. J. (2002) · Nature Medicine · doi:10.1038/nm0502-527 · Cited by 162
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models
Wang, Y., Hallden, G., Hill, R., Anand, A., Liu, T.-C., Francis, J., Brooks, G., Lemoine, N., & Kirn, D. (2003) · Nature Biotechnology · doi:10.1038/nbt887 · Cited by 161
Self-citationIkeda, K., Wakimoto, H., Ichikawa, T., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.10.4765-4775.2000 · Cited by 154
Hermiston, T. W., & Kuhn, I. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700542 · Cited by 135
Hengstschläger, M., Knöfler, M., Müllner, E., Ogris, E., Wintersberger, E., & Wawra, E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36723-6 · Cited by 123
Todo, T., Martuza, R. L., Dallman, M. J., & Rabkin, S. D. (2001) · PubMed · Cited by 89
Law, M., Hollinshead, R., & Smith, G. L. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-1-209 · Cited by 83
Gnant, M., Puhlmann, M., Alexander, H. R., & Bartlett, D. L. (1999) · PubMed · Cited by 82
In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF
Bristol, J. A., Zhu, M., Ji, H. L., Mina, M., Xie, Y., Clarke, L., Forry‐Schaudies, S., & Ennist, D. L. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00103-5 · Cited by 76
Tumor-Specific Gene Delivery Using Recombinant Vaccinia Virus in a Rabbit Model of Liver Metastases
Gnant, M., Noll, L. A., Irvine, K. R., Puhlmann, M., Terrill, R. E., Alexander, H. R., & Bartlett, D. L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.20.1744 · Cited by 71
Replicating vectors for gene therapy of cancer: risks, limitations and prospects
Russell, S. J. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90477-4 · Cited by 56
The role of p16 in the E2F-dependent thymidine kinase regulation.
Hengstschläger, M., Hengstschläger-Ottnad, E., Pusch, O., & Wawra, E. (1996) · PubMed · Cited by 29
Hermiston, T. W., & Kirn, D. H. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.004 · Cited by 14
Self-citation
Cited by
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Heo, J., Reid, T., Ruo, L., Breitbach, C. J., Rose, S., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 779
Self-citationOncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 774
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
Breitbach, C. J., Burke, J., Jonker, D., Stephenson, J., Haas, A. R., Chow, L. Q. M., Nieva, J., Hwang, T.-H., Moon, A., Patt, R., et al. (2011) · Nature · doi:10.1038/nature10358 · Cited by 551
Self-citation
Metadata
- Authors
- Kim, J. H., Oh, J. Y., Park, B. H., Lee, D. E., Kim, J. S., Park, H. E., Roh, M. S., Je, J. E., Yoon, J. H., Thorne, S. H., Kirn, D., & Hwang, T. H.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2006-09
- Volume
- 14
- Issue
- 3
- Pages
- 361-370
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2075631864
- Cited by
- 303
- References
- 34
- FWCI
- 6.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.